BAX vs KRMD
BAX: A diversified healthcare company producing sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, surgical sealants, smart beds, and patient monitoring systems for hospitals and home care globally. KRMD: Koru Medical manufactures FREEDOM Infusion Systems for at-home subcutaneous drug delivery, primarily for immunoglobulin therapy in immunodeficiency diseases, while generating services revenue from pharma partnerships in novel subcutaneous drug development.
Side-by-side fundamentals
| Metric | BAX | KRMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $21.74 | $3.86 | |
| Market cap as of 2026-07-23 | $11.5B | $177M | |
| PEG as of 2026-07-23 | -0.15 | n/a | |
| Net margin as of 2026-07-23 | -9.7% | -5.3% | KRMD higher |
| Gross margin as of 2026-07-23 | +30.7% | +61.9% | KRMD higher |
| Operating margin as of 2026-07-23 | -2.5% | -6.0% | BAX higher |
| ROE as of 2026-07-23 | -16.4% | -13.6% | KRMD higher |
| ROA as of 2026-07-23 | -5.4% | -8.3% | BAX higher |
| Debt / equity as of 2026-07-23 | 1.57 | 0.01 | KRMD lower |
| Revenue growth (YoY) as of 2026-07-23 | -4.8% | +23.3% | KRMD higher |
| Revenue CAGR (3y) SEC XBRL | +3.8% | +13.8% | KRMD higher |
| Dividend yield as of 2026-07-23 | +0.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 0.61 | 0.45 | |
| 1-year return as of 2026-07-22 close | -18.9% | +16.5% | KRMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.